Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of
advanced hepatocellular carcinoma (HCC). However, as the clinical application of sorafenib …

Sorafenib, an orally-available kinase inhibitor, is the only medical treatment with a proven
efficacy against Hepatocellular Carcinoma (HCC). Although the overall clinical efficacy of …

Purpose Preclinical studies show that sorafenib, a multitarget kinase inhibitor, displays anti-
proliferative, anti-angiogenic, and pro-apoptotic properties in hepatocellular carcinoma …

The approval of sorafenib as the first effective drug for the treatment of hepatocellular
carcinoma (HCC) represents a milestone in the treatment of this disease. A better …

Sorafenib is an orally active multikinase inhibitor that targets serine and threonine, and
tyrosine kinases that are involved in tumor‐cell signal transduction and tumor angiogenesis …

Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed
worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced …

Sorafenib is the first and only po administrated drug currently approved to treat advanced
hepatocellular carcinoma (HCC). However, concerns have been raised about sorafenib …

Purpose This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase
and receptor tyrosine kinases, assessed efficacy, toxicity, pharmacokinetics, and biomarkers …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

Sorafenib is a specific adenosine triphosphate–competitive RAF inhibitor used as a first‐line
treatment of advanced hepatocellular carcinoma (HCC). However, the responses are …